Has Roger Bedimo received payments from drug or device companies?

Yes. Drug and device makers reported $269,277 in general payments to Roger Bedimo across 204 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Roger Bedimo did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Roger Bedimo come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Roger Bedimo

Infectious Disease · Dallas, TXNPI 1508879859

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $190,942 of the $269,277 with a category attached, or 70.9%. 9 manufacturers reported payments, led by Viiv Healthcare Company at 32.9% of the total. Among infectious disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$269,277in general payments, 2019–2025

Across 204 payments — averaging $1319.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Viiv Healthcare Company$89K
Merck$69K
Gilead$36K
Shionogi Inc$26K
Theratechnologies Inc.$20K
EMD Serono, Inc.$20K
plus $10K from 3 others

$706,638in research payments, 2019–2025

Across 8 payments — averaging $88,330 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$673K
Viiv Healthcare Company$23K
Novartis$11K

What the payments were for

Consulting fees$190,94271%
Speaking & faculty fees$22,4608%
Grants$940%
Travel & lodging$48,96718%
Food & beverage$4,9272%
Education$1,8861%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Viiv Healthcare Company	53	$88,617
Merck	57	$68,779
Gilead	34	$36,044
Shionogi Inc	29	$26,183
Theratechnologies Inc.	16	$19,936
EMD Serono, Inc.	8	$19,515
GSK	1	$5,808
Janssen Products, LP	5	$4,300
Janssen Scientific Affairs, LLC	1	$94

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ISENTRESS$8,934
STEGLATRO$8,934
PIFELTRO$8,934
DELSTRIGO$8,720
CABENUVA$7,800
DOVATO$7,010
Veklury$5,882
EGRIFTA SV$5,246
Symtuza$4,300
Fetroja$3,908
S-217622$3,150
Biktarvy$2,610
SEROSTIM$1,120
EGRIFTA$234
TROGARZO$234

How this compares

$269,277 in reported general payments places this provider in the 95th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas →

Other infectious disease in Dallas

Elizabeth RaceDallas$1.5M
Uriel SandkovskyDallas$320K
Edward DominguezDallas$121K
Robert HardyDallas$116K
Mezgebe BerheDallas$66K
Ank NijhawanDallas$39K
Philip KeiserDallas$38K
Helen KingDallas$37K
Jason GillmanDallas$24K
David GreenbergDallas$18K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →